AstraZeneca Pharma India Limited EBIT

The latest EBIT for ASTRAZEN.NS is $2.2B as of June 2026. That compares with $2.5B in the prior-year period — down 9.4% year over year. That is below the sector sector average of $2.6T. Investors often review this figure alongside AstraZeneca Pharma India Limited's historical trend and sector peers before judging valuation or financial health.

Over the past year, ASTRAZEN.NS's EBIT moved from $2.5B to $2.2B — a 9.4% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in AstraZeneca Pharma India Limited's operating scale or balance-sheet position.

Against its sector companies, ASTRAZEN.NS currently prints $2.2B for EBIT, while the sector average sits near $2.6T. That is roughly 99.9% below the sector mean. Large gaps often invite a closer look at AstraZeneca Pharma India Limited's growth, margins, and balance sheet.

A EBIT figure of $2.2B for ASTRAZEN.NS is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $2.6T. Explore the charts below for those layers of context.

After noting ASTRAZEN.NS's EBIT ($2.2B), review year-over-year change from $2.5B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.